...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Emerging Infectious Diseases >Intravenous Artesunate for Severe Malaria in Travelers, Europe
【24h】

Intravenous Artesunate for Severe Malaria in Travelers, Europe

机译：欧洲旅行者中严重疟疾的静脉青蒿琥酯

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Multicenter trials in Southeast Asia have shown better survival rates among patients with severe malaria, particularly those with high parasitemia levels, treated with intravenous (IV) artesunate than among those treated with quinine. In Europe, quinine is still the primary treatment for severe malaria. We conducted a retrospective analysis for 25 travelers with severe malaria who returned from malariaendemic regions and were treated at 7 centers in Europe. All patients survived. Treatment with IV artesunate rapidly reduced parasitemia levels. In 6 patients at 5 treatment centers, a self-limiting episode of unexplained hemolysis occurred after reduction of parasitemia levels. Five patients required a blood transfusion. Patients with posttreatment hemolysis had received higher doses of IV artesunate than patients without hemolysis. IV artesunate was an effective alternative to quinine for treatment of malaria patients in Europe. Patients should be monitored for signs of hemolysis, especially after parasitologic cure.
机译：东南亚的多中心试验显示，使用青蒿琥酯静脉注射（IV）治疗的重症疟疾患者，尤其是寄生虫血症高的患者，其存活率更高。在欧洲，奎宁仍然是严重疟疾的主要治疗方法。我们对从疟疾流行地区返回并在欧洲7个中心接受治疗的25名重度疟疾旅客进行了回顾性分析。所有患者均存活。青蒿琥酯静脉注射治疗可以迅速降低寄生虫血症水平。在5个治疗中心的6例患者中，寄生虫血症水平降低后发生了自限性原因不明的溶血。五名患者需要输血。治疗后溶血的患者比未溶血的患者接受更高剂量的静脉注射青蒿琥酯。青蒿琥酯IV是奎宁治疗欧洲疟疾患者的有效替代药物。应该监测患者的溶血迹象，尤其是在寄生虫治愈后。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号